146 related articles for article (PubMed ID: 37271979)
41. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
[TBL] [Abstract][Full Text] [Related]
42. Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.
He X; Huang W; Wan X; Li X; Chang Q; Ding L
J Int Med Res; 2023 Mar; 51(3):3000605231162434. PubMed ID: 36967671
[TBL] [Abstract][Full Text] [Related]
43. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
44. Intravenous Vitamin K1 for the Correction of Prolonged Prothrombin Times in Non-Bleeding Critically Ill Patients: A Prospective Observational Study.
Dahlberg S; Schött U; Eriksson EÄ; Tahirsylaj Y; Schurgers L; Kander T
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444740
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection.
Lv Q; Deng Y; Zhu X; Ruan J; Chen L
J Coll Physicians Surg Pak; 2020 Mar; 30(3):332-334. PubMed ID: 32169149
[TBL] [Abstract][Full Text] [Related]
46. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
47. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment.
Dong Y; Li Y; Zhang Y; Zhang T; Zhu L; Dong Y; Wang T
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):353-359. PubMed ID: 31056857
[TBL] [Abstract][Full Text] [Related]
48. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
Jones RN; Barry AL; Thornsberry C; Wilson HW
Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
[TBL] [Abstract][Full Text] [Related]
49. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.
Chang PC; Chen CC; Lu YC; Lai CC; Huang HL; Chuang YC; Tang HJ
J Microbiol Immunol Infect; 2018 Apr; 51(2):207-213. PubMed ID: 29037802
[TBL] [Abstract][Full Text] [Related]
50. [Clinical evaluation of combination therapy of sulbactam/cefoperazone and aminoglycoside in respiratory tract infections].
Sukoh M; Inoue T; Morita Y; Ito K; Togano Y; Yamanaka K; Hirose S; Takahashi T; Mita S; Mano K
Jpn J Antibiot; 1994 Feb; 47(2):170-80. PubMed ID: 8151910
[TBL] [Abstract][Full Text] [Related]
51. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
[TBL] [Abstract][Full Text] [Related]
52. Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study.
Zhang R; Gao L; Chen P; Liu W; Huang X; Li X
Front Pharmacol; 2023; 14():1170987. PubMed ID: 37361226
[No Abstract] [Full Text] [Related]
53. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections.
Jauregui LE; Appelbaum PC; Fabian TC; Hageage G; Strausbaugh L; Martin LF
J Antimicrob Chemother; 1990 Mar; 25(3):423-33. PubMed ID: 2187014
[TBL] [Abstract][Full Text] [Related]
54. Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
Chen CH; Tu CY; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Lai CC
Infect Drug Resist; 2021; 14():2251-2258. PubMed ID: 34168466
[TBL] [Abstract][Full Text] [Related]
55. Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.
Wang Q; Wu Y; Chen B; Zhou J
BMC Anesthesiol; 2015; 15():33. PubMed ID: 25798070
[TBL] [Abstract][Full Text] [Related]
56. [A trial of using sulperazone (cefoperazone/sulbactam) in the combined treatment of patients with a burn infection].
Iakovlev VP; Krutikov MG; Alekseev AA; Grishina IA; Izotova GN; Kashin IuD
Antibiot Khimioter; 1995 May; 40(5):38-41. PubMed ID: 8534180
[TBL] [Abstract][Full Text] [Related]
57. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study.
Thamprajamchit S; Chetchotisakd P; Thinkhamrop B
J Med Assoc Thai; 1998 Apr; 81(4):265-71. PubMed ID: 9623020
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination for treating intraabdominal infections in an Indian health-care setting.
Kochhar P; Suvarna V; Duttagupta S; Sarkar S
Value Health; 2008 Mar; 11 Suppl 1():S33-8. PubMed ID: 18387065
[TBL] [Abstract][Full Text] [Related]
59. Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.
Schwartz JI; Jauregui LE; Bachmann KA; Martin ME; Reitberg DP
Antimicrob Agents Chemother; 1988 May; 32(5):730-5. PubMed ID: 3395103
[TBL] [Abstract][Full Text] [Related]
60. Treatment efficacy of tigecycline in comparison to cefoperazone/ sulbactam alone or in combination therapy for carbapenenm-resistant Acinetobacter baumannii infections.
Li Y; Xie J; Chen L; Meng T; Liu L; Hao R; Dong H; Wang X; Dong Y
Pak J Pharm Sci; 2020 Jan; 33(1):161-168. PubMed ID: 32122844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
